According to a study published in the New England Journal of Medicine a combination of two common antiretroviral drugs if taken daily will reduce the risk of transmission in men who have sex with men. Nearly 2500 mean were either given a combination of emtritabin and tenofovir, know as PrEP, or a placebo. The risk was reduced by 44% in those recieving PrEP, and 73% in those who had taken it for a year.
"We now have strong evidence that pre-exposure prophylaxis with an antiretroviral drug, a strategy widely referred to as PrEP, can reduce the risk of HIV acquisition among men who have sex with men, a segment of the population disproportionately affected by HIV/AIDS," says Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID).